NZ631187A - Tricyclic quinoline and quinoxaline derivatives - Google Patents
Tricyclic quinoline and quinoxaline derivativesInfo
- Publication number
- NZ631187A NZ631187A NZ631187A NZ63118713A NZ631187A NZ 631187 A NZ631187 A NZ 631187A NZ 631187 A NZ631187 A NZ 631187A NZ 63118713 A NZ63118713 A NZ 63118713A NZ 631187 A NZ631187 A NZ 631187A
- Authority
- NZ
- New Zealand
- Prior art keywords
- diazepino
- quinoline
- quinoxaline
- hexahydro
- quinolin
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 4
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- FKSSHOPSFPRKAN-GFCCVEGCSA-N (12R)-7,10,16-triazatetracyclo[8.6.1.05,17.012,16]heptadeca-1,3,5(17)-triene Chemical compound C1CNCC2=CC=CC3=C2N1C[C@H]1CCCN13 FKSSHOPSFPRKAN-GFCCVEGCSA-N 0.000 abstract 1
- AHWINIOXMHFXRH-UHFFFAOYSA-N 1-fluoro-5,6,7,9,9a,10,11,12-octahydro-4h-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline Chemical compound C12=C3C(F)=CC=C2CNCCN1CC1N3CCC1 AHWINIOXMHFXRH-UHFFFAOYSA-N 0.000 abstract 1
- ZYTJBRCFLDIGMV-UHFFFAOYSA-N 16-methyl-7,10-diazatetracyclo[8.6.1.05,17.012,16]heptadeca-1,3,5(17)-triene Chemical compound C1CNCC2=CC=CC3=C2N1CC1CCCC13C ZYTJBRCFLDIGMV-UHFFFAOYSA-N 0.000 abstract 1
- IGGKJFGTZCPRDN-UHFFFAOYSA-N 2,3,5,6,7,8-hexahydro-1h-[1,4]diazepino[1,7,6-de]quinoxaline Chemical compound C1CNCC2=CC=CC3=C2N1CCN3 IGGKJFGTZCPRDN-UHFFFAOYSA-N 0.000 abstract 1
- LAKZLGUTIVXKGU-UHFFFAOYSA-N 4,11-dimethyl-1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-trien-4-ol Chemical compound C1N(C)CCN2CCC(C)(O)C3=CC=CC1=C23 LAKZLGUTIVXKGU-UHFFFAOYSA-N 0.000 abstract 1
- USVPKQYKHVMSSP-UHFFFAOYSA-N 4,4-dimethyl-1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-trien-2-one Chemical compound C1CNCC2=CC=CC3=C2N1C(=O)CC3(C)C USVPKQYKHVMSSP-UHFFFAOYSA-N 0.000 abstract 1
- XHEDDWTXFCYRQL-UHFFFAOYSA-N 4-cyclobutyl-1,4,11-triazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-triene Chemical compound C1CCC1N1C(C=CC=C2CNCC3)=C2N3CC1 XHEDDWTXFCYRQL-UHFFFAOYSA-N 0.000 abstract 1
- RLJXLVOZTUAUGB-UHFFFAOYSA-N 4-methyl-1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-trien-4-ol Chemical compound C1CNCC2=CC=CC3=C2N1CCC3(O)C RLJXLVOZTUAUGB-UHFFFAOYSA-N 0.000 abstract 1
- FVRKOPKMEZYHSP-UHFFFAOYSA-N 4-methyl-4-phenyl-1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-trien-2-one Chemical compound C1C(=O)N(C=23)CCNCC3=CC=CC=2C1(C)C1=CC=CC=C1 FVRKOPKMEZYHSP-UHFFFAOYSA-N 0.000 abstract 1
- JELKPZCVCMCSGA-UHFFFAOYSA-N 4-propyl-1,4,11-triazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-triene Chemical compound C1CNCC2=CC=CC3=C2N1CCN3CCC JELKPZCVCMCSGA-UHFFFAOYSA-N 0.000 abstract 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 abstract 1
- KZFPJZJRYLCSIJ-UHFFFAOYSA-N 6-chloro-4,4-dimethyl-1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-triene Chemical compound C1CNCC2=CC=C(Cl)C3=C2N1CCC3(C)C KZFPJZJRYLCSIJ-UHFFFAOYSA-N 0.000 abstract 1
- QFFPEJGHEWLBEY-UHFFFAOYSA-N 6-fluoro-10-methylspiro[1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-triene-4,1'-cyclobutane] Chemical compound C=12C3=C(F)C=CC=1C(C)NCCN2CCC13CCC1 QFFPEJGHEWLBEY-UHFFFAOYSA-N 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- NQRFHPFJQSARLD-UHFFFAOYSA-N spiro[1,11-diazatricyclo[7.4.1.05,14]tetradeca-5,7,9(14)-triene-4,1'-cyclohexane] Chemical compound C1CCCCC21C(C=CC=C1CNCC3)=C1N3CC2 NQRFHPFJQSARLD-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- NPTIPEQJIDTVKR-STQMWFEESA-N vabicaserin Chemical class C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701514P | 2012-09-14 | 2012-09-14 | |
| US201261701531P | 2012-09-14 | 2012-09-14 | |
| US201361793033P | 2013-03-15 | 2013-03-15 | |
| CN201310410951.1A CN104418862A (zh) | 2013-09-11 | 2013-09-11 | 三环喹啉和喹喔啉衍生物 |
| PCT/EP2013/069036 WO2014041131A1 (en) | 2012-09-14 | 2013-09-13 | Tricyclic quinoline and quinoxaline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ631187A true NZ631187A (en) | 2017-03-31 |
Family
ID=50275085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ631187A NZ631187A (en) | 2012-09-14 | 2013-09-13 | Tricyclic quinoline and quinoxaline derivatives |
Country Status (26)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428506B2 (en) | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| TWI662030B (zh) | 2013-01-15 | 2019-06-11 | 英塞特控股公司 | 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| KR102967223B1 (ko) | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| US9540376B2 (en) | 2014-03-14 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Hexahydrodiazepinoquinolines carrying a substituted alkyl radical |
| US9573950B2 (en) | 2014-03-14 | 2017-02-21 | Abbvie Deutschland Gmbh & Co Kg | Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| HUE047169T2 (hu) * | 2015-04-27 | 2020-04-28 | Arena Pharm Inc | 5-HT2C receptor agonisták és készítmények és felhasználási eljárások |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| JP6789578B2 (ja) * | 2015-07-31 | 2020-11-25 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法 |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| RU2743513C2 (ru) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| IL281050B2 (en) | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
| US20200392135A1 (en) * | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| SMT202600133T1 (it) * | 2018-03-23 | 2026-05-12 | Intra Cellular Therapies Inc | Composti organici |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20210104785A (ko) | 2018-12-17 | 2021-08-25 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| WO2021119334A1 (en) | 2019-12-11 | 2021-06-17 | Intra-Cellular Therapies, Inc. | Organic compound |
| KR102600176B1 (ko) * | 2021-10-18 | 2023-11-10 | 주식회사 사피엔스바이오 | 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| CA3235125A1 (en) * | 2021-10-18 | 2023-04-27 | Dong-Oh Yoon | Novel compound and pharmaceutical composition comprising same |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| KR102715926B1 (ko) * | 2022-06-10 | 2024-10-15 | 주식회사 사피엔스바이오 | 신규한 화합물 및 이를 유효성분으로 포함하는 약학적 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714149A (en) | 1969-11-03 | 1973-01-30 | Upjohn Co | Pyridobenzodiazepinones |
| EP0480939B1 (en) | 1989-06-09 | 1995-01-25 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
| WO1998027097A1 (en) * | 1996-12-16 | 1998-06-25 | Warner-Lambert Company | Tricyclic quinoxaline derivatives as neuroprotective agents |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| WO2002036596A2 (en) * | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| TWI312781B (en) * | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| US20080146583A1 (en) | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
| ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| JP2009531435A (ja) | 2006-03-24 | 2009-09-03 | ワイス | うつ病の治療用の新規な治療組み合わせ |
| EP1998781A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Treatment of pain |
| WO2007112073A2 (en) | 2006-03-24 | 2007-10-04 | Wyeth | Methods for modulating bladder function |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| EP2421870B1 (en) * | 2009-04-23 | 2016-03-09 | AbbVie Inc. | Modulators of 5-ht receptors and methods of use thereof |
| US20140080813A1 (en) * | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
-
2013
- 2013-09-13 BR BR112015005743A patent/BR112015005743A2/pt not_active IP Right Cessation
- 2013-09-13 IN IN2070DEN2015 patent/IN2015DN02070A/en unknown
- 2013-09-13 CA CA2884548A patent/CA2884548A1/en not_active Abandoned
- 2013-09-13 UA UAA201503409A patent/UA116216C2/uk unknown
- 2013-09-13 CN CN201380059579.2A patent/CN104995191A/zh active Pending
- 2013-09-13 NZ NZ631187A patent/NZ631187A/en not_active IP Right Cessation
- 2013-09-13 PE PE2015000363A patent/PE20150777A1/es not_active Application Discontinuation
- 2013-09-13 AR ARP130103294A patent/AR092568A1/es unknown
- 2013-09-13 SG SG11201501894VA patent/SG11201501894VA/en unknown
- 2013-09-13 UY UY0001035029A patent/UY35029A/es not_active Application Discontinuation
- 2013-09-13 HK HK16100520.1A patent/HK1212684A1/zh unknown
- 2013-09-13 KR KR1020157009502A patent/KR20150056608A/ko not_active Withdrawn
- 2013-09-13 RU RU2015113558A patent/RU2015113558A/ru not_active Application Discontinuation
- 2013-09-13 WO PCT/EP2013/069036 patent/WO2014041131A1/en not_active Ceased
- 2013-09-13 AU AU2013314279A patent/AU2013314279B2/en not_active Ceased
- 2013-09-13 US US14/026,354 patent/US10118926B2/en active Active
- 2013-09-13 JP JP2015531577A patent/JP6290217B2/ja not_active Expired - Fee Related
- 2013-09-13 EP EP13762483.9A patent/EP2895485A1/en not_active Withdrawn
- 2013-09-13 MX MX2015003364A patent/MX2015003364A/es unknown
- 2013-09-14 TW TW102133403A patent/TW201414735A/zh unknown
-
2015
- 2015-03-12 IL IL237726A patent/IL237726A0/en unknown
- 2015-03-13 PH PH12015500551A patent/PH12015500551A1/en unknown
- 2015-03-13 DO DO2015000058A patent/DOP2015000058A/es unknown
- 2015-03-13 CL CL2015000628A patent/CL2015000628A1/es unknown
- 2015-04-01 EC ECIEPI201512766A patent/ECSP15012766A/es unknown
- 2015-04-10 CR CR20150186A patent/CR20150186A/es unknown
-
2018
- 2018-01-24 AU AU2018200572A patent/AU2018200572A1/en not_active Abandoned
- 2018-11-02 US US16/179,050 patent/US20190071443A1/en not_active Abandoned
-
2019
- 2019-10-14 US US16/601,075 patent/US20200283439A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150056608A (ko) | 2015-05-26 |
| TW201414735A (zh) | 2014-04-16 |
| US20200283439A1 (en) | 2020-09-10 |
| JP2015528478A (ja) | 2015-09-28 |
| PE20150777A1 (es) | 2015-06-20 |
| SG11201501894VA (en) | 2015-04-29 |
| US20190071443A1 (en) | 2019-03-07 |
| US10118926B2 (en) | 2018-11-06 |
| EP2895485A1 (en) | 2015-07-22 |
| IN2015DN02070A (cg-RX-API-DMAC7.html) | 2015-08-14 |
| RU2015113558A (ru) | 2016-11-10 |
| AU2013314279A1 (en) | 2015-04-02 |
| MX2015003364A (es) | 2016-03-31 |
| AR092568A1 (es) | 2015-04-22 |
| CA2884548A1 (en) | 2014-03-20 |
| BR112015005743A2 (pt) | 2017-07-04 |
| CL2015000628A1 (es) | 2015-10-30 |
| JP6290217B2 (ja) | 2018-03-07 |
| AU2018200572A1 (en) | 2018-02-15 |
| CN104995191A (zh) | 2015-10-21 |
| UY35029A (es) | 2014-04-30 |
| WO2014041131A1 (en) | 2014-03-20 |
| CR20150186A (es) | 2015-08-28 |
| US20140080816A1 (en) | 2014-03-20 |
| DOP2015000058A (es) | 2015-04-15 |
| IL237726A0 (en) | 2015-05-31 |
| PH12015500551A1 (en) | 2015-05-04 |
| HK1212684A1 (zh) | 2016-06-17 |
| UA116216C2 (uk) | 2018-02-26 |
| ECSP15012766A (es) | 2017-06-30 |
| AU2013314279B2 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150777A1 (es) | Derivados triciclicos de quinolinas y de quinoxalinas | |
| NZ627900A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| KR102165113B1 (ko) | Ａ2ａ 길항제 성질을 갖는 헤테로비시클로-치환된-[1,2,4]트리아졸로[1,5-ｃ]퀴나졸린-5-아민 화합물 | |
| AR131260A2 (es) | Compuestos para tratar atrofia muscular espinal | |
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| NZ624068A (en) | Fused tricyclic compounds as raf kinase inhibitors | |
| TN2011000244A1 (en) | Organic compounds | |
| NZ711948A (en) | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one | |
| MX2021001096A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| EP3489238B8 (en) | Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders | |
| WO2018226622A1 (en) | Compounds for treating huntington's disease | |
| CO6531468A2 (es) | Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10 | |
| JP2017524702A (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| NZ712802A (en) | Novel n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| MX2013007148A (es) | 2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina. | |
| NZ609200A (en) | Buprenorphine analogs | |
| WO2012143416A3 (en) | 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
| NZ712378A (en) | Synthetic methods for spiro-oxindole compounds | |
| UA99459C2 (en) | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer | |
| BRPI1012159A2 (pt) | derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase. | |
| MX2011008452A (es) | Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata. | |
| TW200821315A (en) | Benzofuro-and benzothienopyrimidine modulators of the histamine H4 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 SEP 2018 BY THOMSON REUTERS Effective date: 20170720 |
|
| LAPS | Patent lapsed |